NCT05118906View on ClinicalTrials.gov

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Binge-Eating Disorder
Interventions
DRUG

BP1.4979 active drug

2 tablets 15 mg of BP1.4979 per day

DRUG

Placebo

2 tablets of placebo per day

Trial Locations (1)

75013

Nutrition Department, La Pitié Salpêtrière Hospital, Paris

Sponsors

Lead Sponsor

Bioprojet
All Listed Sponsors
lead

Bioprojet

OTHER